In an increasingly complex pharmaceutical landscape, companies face significant challenges in bringing their products from development to market efficiently and seamlessly. The fragmentation of CDMO services, lack of integration between development and manufacturing, and uncertainties in cost and technical feasibility often lead to delays, increased risks, and higher expenses. How can pharmaceutical companies secure a streamlined, reliable, and cost-effective pathway from early development to commercial production?

This webinar aims to answer that question by presenting Fareva’s unique approach as an end-to-end CDMO. With a fully integrated offer, Fareva eliminates the traditional hurdles of fragmented outsourcing by ensuring a seamless transition from pharmaceutical development to industrial-scale manufacturing. Our three GMP pilot sites support product development and technical transfers across fifteen manufacturing facilities, providing a structured and predictable process for our clients. By aligning development and manufacturing from the outset, we simplify project management with a single point of contact, ensure cost visibility, and accelerate time-to-market.

The session will also highlight Fareva’s specialized expertise in high-potency oral solid doses, sterile manufacturing, and biologics, demonstrating how our tailored solutions can support even the most complex pharmaceutical developments. We will explore real-world examples, including how we successfully transferred an mRNA vaccine in record time, overcoming major technical challenges with speed and precision.

Through this presentation, you will gain a clearer understanding of how working with a development-driven CDMO can mitigate risks, optimize resources, and ensure a successful pathway to commercialization. 

Speakers:

Philippe Rampignon – VP Pharmaceutical R&D, Fareva

Aude Rémond – Corporate Quality Director, BU Pharma & API Fareva